pharma · Renal Transplantation · Rheumatoid Arthritis (RA)
Astellas Pharma
Astellas Pharma Inc
Astellas Pharma clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 20
- Drugs
- 12
- Patents
- 25
Astellas Pharma projects
10 ClinicalTrials.gov programs sponsored by Astellas Pharma.
Astellas Pharma has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ASP8825
Astellas Pharma Inc
Restless Legs Syndrome
1 trial -
Fezolinetant
Astellas Pharma Inc
Hot Flashes
1 trial -
Isavuconazole
Astellas Pharma Inc
Candidiasis, Invasive
1 trial -
Mirabegron
Astellas Pharma Inc
Overactive Bladder (OAB)
1 trial -
Ramosetron
Astellas Pharma Inc
Vomiting
1 trial -
Tacrolimus capsule
Astellas Pharma Inc
Myasthenia Gravis
1 trial -
YM060
Astellas Pharma Inc
Diarrhea-predominant Irritable Bowel Syndrome
1 trial -
gilteritinib
Astellas Pharma Inc
Acute Myeloid Leukemia (AML)
1 trial -
linaclotide
Astellas Pharma Inc
Chronic Constipation
1 trial -
tacrolimus
Astellas Pharma Inc
Kidney Transplantation
1 trial
Frequently asked questions
How many clinical projects does Astellas Pharma have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.